Fusion Pharmaceuticals Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2025-02-26: Study NCT06909825; Company role Lead sponsor; Phase Phase 2; Status Active not recruiting.
- 2024-03-05: Study NCT06402331; Company role Lead sponsor; Phase Phase 2; Status Active not recruiting.
- 2022-04-20: Study NCT05363605; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Terminated.
- 2021-12-16: Study NCT05219500; Company role Lead sponsor; Phase Phase 2; Status Active not recruiting.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2025-02-26 | NCT06909825 FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Lead sponsor | Phase 2 | Active not recruiting | Metastatic Castration-resistant Prostate Cancer | 85 | 2027-05 |
| 2024-03-05 | NCT06402331 FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Lead sponsor | Phase 2 | Active not recruiting | Metastatic Castration-resistant Prostate Cancer | 110 | 2031-01-23 |
| 2022-04-20 | NCT05363605 A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Lead sponsor | Phase 1, Phase 2 | Terminated | Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma; Bladder Carcinoma; Susceptible FGFR3 Genetic Alterations; FGFR3; FGFR3 Overexpression; FGFR3 Receptor; FGFR3 Protein Overexpression; Ovarian Cancer; Colorectal Cancer; Breast Cancer; Liver Cancer; Lung Cancer; Gastric Cancer | 6 | 2023-09-08 |
| 2021-12-16 | NCT05219500 Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). | Lead sponsor | Phase 2 | Active not recruiting | Metastatic Castration Resistant Prostate Cancer | 115 | 2026-07-31 |
| 2019-01-17 | NCT03746431 A Phase 1 Study of [225Ac]-FPI-1434 Injection | Lead sponsor | Phase 1 | Terminated | Advanced Solid Tumours; Endometrial Cancer; Cervical Cancer; Ovarian Cancer; Breast Cancer; Triple Negative Breast Cancer (TNBC); HER2-negative Breast Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC); Adrenocortical Carcinoma; Uveal Melanoma | 78 | 2025-12-03 |